The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cardiovascular Safety of Testosterone-Replacement Therapy
Abstract
BACKGROUND: The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been determined. METHODS: In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who reported symptoms of hypogonadism and had two fasting testosterone levels of less than 300 ng per deciliter. Patients were randomly assigned to receive daily transdermal 1.62% testosterone gel (dose adjusted to maintain testosterone levels between 350 and 750 ng per deciliter) or placebo gel. The primary cardiovascular safety end point was the first occurrence of any component of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, assessed in a time-to-event analysis. A secondary cardiovascular end point was the first occurrence of any component of the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, assessed in a time-to-event analysis. Noninferiority required an upper limit of less than 1.5 for the 95% confidence interval of the hazard ratio among patients receiving at least one dose of testosterone or placebo. RESULTS: The mean (±SD) duration of treatment was 21.7±14.1 months, and the mean follow-up was 33.0±12.1 months. A primary cardiovascular end-point event occurred in 182 patients (7.0%) in the testosterone group and in 190 patients (7.3%) in the placebo group (hazard ratio, 0.96; 95% confidence interval, 0.78 to 1.17; P<0.001 for noninferiority). Similar findings were observed in sensitivity analyses in which data on events were censored at various times after discontinuation of testosterone or placebo. The incidence of secondary end-point events or of each of the events of the composite primary cardiovascular end point appeared to be similar in the two groups. A higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism was observed in the testosterone group. CONCLUSIONS: In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,930
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationVigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Self-citationCardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Nissen, S. E., Yeomans, N. D., Solomon, D. H., Lüscher, T. F., Libby, P., Husni, M. E., Graham, D. Y., Borer, J. S., Wisniewski, L. M., Wolski, K. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611593 · Cited by 856
Self-citationIncreased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735
Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566
Xu, L., Freeman, G., Cowling, B. J., & Schooling, C. M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-108 · Cited by 563
Testosterone treatment and mortality in men with low testosterone levels
Shores, M. M., Smith, N. L., Forsberg, C. W., Anawalt, B. D., & Matsumoto, A. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2591 · Cited by 460
Bachman, E., Travison, T. G., Basaria, S., Davda, M. N., Guo, W., Li, M., Connor Westfall, J., Bae, H., Gordeuk, V., & Bhasin, S. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt154 · Cited by 426
Self-citationSteidle, C., Schwartz, S., Jacoby, K., Sebree, T., Smith, T., & Bachand, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021058 · Cited by 411
Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S., & Jones, T. H. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0321 · Cited by 389
Snyder, P. J., Kopperdahl, D. L., Stephens-Shields, A. J., Ellenberg, S. S., Cauley, J. A., Ensrud, K. E., Lewis, C. E., Barrett-Connor, E., Schwartz, A. V., Lee, D. C., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9539 · Cited by 363
Self-citationCorona, G., Maseroli, E., Rastrelli, G., Isidori, A. M., Sforza, A., Mannucci, E., & Maggi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.950653 · Cited by 297
Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273
Self-citationBasaria, S., Harman, S. M., Travison, T. G., Hodis, H., Tsitouras, P., Budoff, M., Pencina, K. M., Vita, J., Dzekov, C., Mazer, N. A., et al. (2015) · JAMA · doi:10.1001/jama.2015.8881 · Cited by 268
Self-citationCardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808721 · Cited by 265
Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial
Roy, C. N., Snyder, P. J., Stephens-Shields, A. J., Artz, A. S., Bhasin, S., Cohen, H. J., Farrar, J. T., Gill, T. M., Zeldow, B., Cella, D., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9540 · Cited by 239
Self-citationRisk of Myocardial Infarction in Older Men Receiving Testosterone Therapy
Baillargeon, J., Urban, R. J., Kuo, Y.-F., Ottenbacher, K. J., Raji, M. A., Du, F., Lin, Y.-L., & Goodwin, J. S. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014539918 · Cited by 203
Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels
Cunningham, G. R., Stephens-Shields, A. J., Rosen, R. C., Wang, C., Bhasin, S., Matsumoto, A. M., Parsons, J. K., Gill, T. M., Molitch, M. E., Farrar, J. T., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1645 · Cited by 162
Self-citationTestosterone therapy in hypogonadal men: a systematic review and network meta-analysis
Elliott, J., Kelly, S., Millar, A. C., Peterson, J., Chen, L., Johnston, A., Kotb, A., Skidmore, B., Bai, Z., Mamdani, M., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015284 · Cited by 162
Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis
Alexander, G. C., Iyer, G. S., Lucas, E. J., Lin, D. H., & Singh, S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.09.017 · Cited by 126
Hudson, J., Cruickshank, M., Quinton, R., Aucott, L. S., Aceves‐Martins, M., Gillies, K., Bhasin, S., Snyder, P. J., Ellenberg, S. S., Grossmann, M., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00096-4 · Cited by 122
Self-citationOnasanya, O., Iyer, G. S., Lucas, E. J., Lin, D. H., Singh, S., & Alexander, G. C. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30215-7 · Cited by 114
Brock, G., Heiselman, D., Maggi, M., Kim, S. W., Rodríguez Vallejo, J. M., Behre, H. M., McGettigan, J., Dowsett, S. A., Hayes, R. P., Knorr, J., et al. (2016) · Journal of Urology · doi:10.1016/j.juro.2015.10.083 · Cited by 109
New methods for estimating follow-up rates in cohort studies
Xue, X., Agalliu, I., Kim, M., Wang, T., Lin, J., Ghavamian, R., & Strickler, H. D. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0436-z · Cited by 93
Bhasin, S., Lincoff, A. M., Basaria, S. S., Bauer, D. C., Boden, W. E., Cunningham, G. R., Davey, D. A., Dubcenco, E., Fukumoto, S., Garcia, M., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.11.016 · Cited by 91
Self-citationSharma, R., Oni, O. A., Gupta, K., Sharma, M., Sharma, R., Singh, V., Parashara, D., Surineni, K., Dawn, B., Chen, G., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004880 · Cited by 87
Testosterone therapy, thrombosis, thrombophilia, cardiovascular events
Glueck, C. J., & Wang, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.005 · Cited by 84
White, W. B., Bernstein, J. S., Rittmaster, R. S., et al. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14297 · Cited by 26
Cited by
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 360
Lampert, R., Chung, E. H., Ackerman, M. J., Arroyo, A. R., Darden, D., Deo, R., Dolan, J., Etheridge, S. P., Gray, B. R., Harmon, K. G., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.05.018 · Cited by 167
Salonia, A., Capogrosso, P., Boeri, L., Cocci, A., Corona, G., Dinkelman-Smit, M., Falcone, M., Jensen, C. F., Gül, M., Kalkanli, A., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.04.010 · Cited by 174
Theodorakis, N., Feretzakis, G., Vamvakou, G., Verykios, V. S., Polymeris, A., & Nikolaou, M. (2024) · Hormones · doi:10.1007/s42000-024-00587-2 · Cited by 28
Metadata
- Authors
- Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., Wang, Q., Wolski, K., Davey, D., Kalahasti, V., Khan, N., Miller, M. G., Snabes, M. C., Chan, A., Dubcenco, E., Li, X., Yi, T., Huang, B., Pencina, K. M., Travison, T. G., & Nissen, S. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-07-13
- Volume
- 389
- Issue
- 2
- Pages
- 107-117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4380872196
- Cited by
- 475
- References
- 32
- FWCI
- 78.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- AbbVie
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.